Found 1 Presentation For Request "1009p"
1009P - Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib
- Sai-Hong I. Ou (Orange, United States of America)
Abstract
Background
The ALK inhibitor alectinib is a standard-of-care option for
Methods
ALTA-2 (NCT03535740) and J-ALTA (NCT03410108) enrolled 133 pts (ALTA-2, 86 pts; J-ALTA, 47 pts) with advanced
Results
Of the 133 pts who progressed on alectinib, with or without prior crizotinib or chemotherapy, 131 had evaluable baseline plasma data. Brigatinib efficacy parametersa according to baseline ALK mutation status a Blinded independent review committee–-assessed CI, confidence interval
n Confirmed ORR, Median DoR, mo (95% CI) Median PFS, mo (95% CI) Without detectable 54 37.0 (24.3–51.3) NA (9.2–NA) 9.3 (7.5–NA) With detectable 77 26.0 (16.6–37.2) 5.3 (3.7–NA) 3.5 (1.8–5.2) With secondary 29 34.5 (17.9–54.3) 5.6 (3.5–NA) 3.7 (1.8–5.6) Without secondary 97 29.9 (21.0–40.0) NA (5.7–NA) 5.6 (3.8–9.2)
Conclusions
Brigatinib showed clinically meaningful activity in pts with alectinib-resistant
Clinical trial identification
NCT03535740; NCT03410108.
Editorial acknowledgement
Professional medical writing assistance was provided by Braden Roth, PhD, and Lauren Gallagher, RPh, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Takeda Development Center Americas, Inc., Lexington, MA, USA.
Legal entity responsible for the study
Takeda Pharmaceutical Company Limited, Tokyo, Japan, and Takeda Development Center Americas, Inc., Lexington, MA, USA.
Funding
Takeda Pharmaceutical Company Limited, Tokyo, Japan, and Takeda Development Center Americas, Inc., Lexington, MA, USA.
Disclosure
S.I. Ou: Financial Interests, Personal, Invited Speaker: Pfizer, Roche; Financial Interests, Personal, Advisory Board: JNJ/Janssen, Elevation Oncology; Financial Interests, Personal, Stocks/Shares: Turning Point Therapeutics, Elevation Oncology; Financial Interests, Institutional, Invited Speaker: Pfizer, Mirati, JNJ/jassen, Merus. M. Nishio: Financial Interests, Personal, Other, grants and personal fees: Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, Novartis, Daiichi Sankyo, Takeda Pharmaceutical Company Limited; Financial Interests, Personal, Other, personal fees: Boehringer Ingelheim, Merck Biopharma, Teijin Pharma Limited, AbbVie. T. Yoshida: Financial Interests, Personal, Other, Honoraria: AstraZeneca, MSD Oncology, Ono Pharmaceutical, Chugai/Roche, Lilly Japan, Nippon Boehringer Ingelheim, Bristol Myers Squibb Japan, Novartis, Archer DX, Takeda, Pfizer; Financial Interests, Personal, Other, consulting or advisory role: Lilly Japan, Chugai/Roche, Novartis, Boehringer Ingelheim, AstraZeneca; Financial Interests, Institutional, Funding: Chugai/Roche, AstraZeneca, AbbVie, Amgen, MSD, Bristol Myers Squibb, Ono Pharmaceutical, Takeda, Daiichi Sankyo, Novartis. M. Ahn: Financial Interests, Personal, Advisory Board: AstraZeneca, Lilly, Takeda, MSD, Yuhan, Amgen, Alpha Pharmaceutical, Janssen, BMS, Roche, Daichi Sankyo. T.S.K. Mok: Financial Interests, Personal, Invited Speaker: AbbVie, Acea Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Daiichi Sankyo, Fishawack Facilitate, InMed Medical Communication, Lunit USA, Inc., Merck Serono, MSD, Roche, MD Health, Medscape/WebMD, PeerVoice, Permanyer SL, Prime Oncology, Research to Practice, Touch Medical Media, Sanofi-Aventis, Takeda, PER, AstraZeneca, Hutchison Chi-Med; Financial Interests, Personal, Advisory Board: AbbVie, Acea Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Blueprint Medicines, Berry Oncology, CStone Pharma, Daiichi Sankyo, Fishawack Facilitate, Eisai, Gritstone Oncology, Guardant Health, G1 Therapeutics, Hengrui, Ignyta, IQVIA, Incyte Corporation, Inivata, Janssen, Loxo Oncology, Qiming Dev., Lunit USA, Inc., Merck Serono, MSD, Roche, Mirati Therapeutics, MoreHealth, Novartis, OrigiMed, Puma Tech., Sanofi-Aventis, Takeda, Virtus Medical, Yuhan, Curio Science; Financial Interests, Personal, Stocks/Shares: Sanomics Ltd., Hutchison Chi-Med, Biolidics Ltd., Loxo Oncology, OrigiMed Co., Virtus Medical Group, Lunit USA, Inc., Aurora Tele-Oncology; Financial Interests, Institutional, Funding, For clinical trials performed at CUHK: AstraZeneca, BMS, Merck Serono, MSD, Novartis, Pfizer, Roche, SFJ Pharmaceuticals, XCovery, Takeda, G1 Therapeutics, Clovis Oncology; Non-Financial Interests, Advisory Role: geneDecode, AstraZeneca; Non-Financial Interests, Other, Invited Speaker: AstraZeneca; Non-Financial Interests, Invited Speaker: Aurora Tele-Oncology, Lunit USA, Inc., Sanomics Ltd.; Non-Financial Interests, Leadership Role: American Society of Clinical Oncology (ASCO), Asian Thoracic Oncology Research Group (ATORG), Chinese Lung Cancer Research Foundation Limited (CLCRF), Chinese Society of Clinical Oncology (CSCO), Hong Kong Cancer Fund (HKCF), Hong Kong Cancer Therapy Society (HKCTS), St. Stephen’s College & Prep. School (Hong Kong); Non-Financial Interests, Leadership Role, Term ended on 30 April 2019: International Association for the Study of Lung Cancer (IASLC). K. Kudou, T. Asato, H. Yang, X. Tong, P. Zhang: Financial Interests, Personal, Full or part-time Employment: Takeda. N. Yamamoto: Financial Interests, Personal, Invited Speaker: MSD K.K, AstraZeneca, Ono Pharmaceutical Co., Ltd., Thermo Fisher Scientific, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Boehringer Ingelheim, Novartis, Pfizer Inc., Bristol-Myers Squibb, Nippon Kayaku, GlaxoSmithKline K.K., Sanofi K.K., Hisamitsu Pharmaceutical Co., Inc., Merck Biopharma; Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Boehringer Ingelheim, Novartis, Bristol-Myers Squibb, Nippon Kayaku, Life Technologies Japan Ltd., Amgen Inc., Guardant Health Japan, Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: MSD K.K; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Amgen Inc., Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Funding: Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Toppan Printing, Terumo. E.S. Kim: Financial Interests, Personal, Other, Consulting and research: AstraZeneca, Roche/Genentech, Mirati.